Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643223 | 0.89 | KMT2A (0.49) | KMT2AMEN1GAATDP1RAB9A | |
| SCHEMBL2643873 | 0.89 | KMT2A (0.46) | KMT2AMEN1GAATDP1TP53 | |
| SCHEMBL2642769 | 0.87 | KMT2A (0.44) | KMT2AMEN1GAATDP1CACNA1G | |
| SCHEMBL2644277 | 0.87 | ALDH1A1 (0.48) | KMT2AMEN1GAATDP1NPC1 | |
| SCHEMBL1617890 | 0.84 | KDM4E (0.39) | KMT2AGAATDP1NPC1RAB9A | |
| SCHEMBL2644224 | 0.84 | KMT2A (0.41) | KMT2AMEN1GAATDP1NPC1 | |
| SCHEMBL2643343 | 0.83 | KMT2A (0.44) | KMT2AMEN1GAATDP1NPC1 | |
| SCHEMBL2644714 | 0.83 | NPC1 (0.47) | KMT2AMEN1TDP1NPC1RAB9A | |
| SCHEMBL2643281 | 0.81 | SMN1; SMN2 (0.53) | KMT2AMEN1GAATDP1NPC1 | |
| SCHEMBL2642742 | 0.79 | FAAH (0.41) | KMT2AMEN1GAATDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680122-B2 | Substituted pyrrolones as allosteric modulators of glucokinase | JANSSEN PHARMACETICA N.V. (BE) | 2014-03-25 | — | — | US | disclosed |
| US-8680122-B2 | Substituted pyrrolones as allosteric modulators of glucokinase | JANSSEN PHARMACETICA N.V. (BE) | 2014-03-25 | — | — | US | disclosed |
| US-8680122-B2 | Substituted pyrrolones as allosteric modulators of glucokinase | JANSSEN PHARMACETICA N.V. (BE) | 2014-03-25 | — | — | US | disclosed |
| US-20070099937-A1 | Substituted Pyrrolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099937-A1 | Substituted Pyrrolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099937-A1 | Substituted Pyrrolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099937-A1 | Substituted Pyrrolones As Allosteric Modulators of Glucokinase | GCK, GCKR, PDXK | KMT2A 3063/4885MEN1 4513/4885GAA 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.